logo
welcome
CNBC

CNBC

Health

Health

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says

CNBC
Summary
Nutrition label

74% Informative

The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years .

The active ingredient in both of the drugs, semaglutide, has been in shortage in the US since 2022 after demand skyrocketed.

The FDA 's decision will threaten the ability of compounding pharmacies to make cheaper, unbranded versions of the injections.

VR Score

72

Informative language

72

Neutral language

11

Article tone

formal

Language

English

Language complexity

66

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

1

Affiliate links

no affiliate links